Adipose‐derived stromal/stem cells successfully attenuate the fibrosis of scleroderma mouse models

Abstract

Abstract Aim Systemic sclerosis (SSc) is an autoimmune disease characterized by skin and lung fibrosis. Although SSc has a high mortality risk, an effective treatment for the disease has not been established yet. Mesenchymal stromal/stem cells (MSCs) are multipotential nonhematopoietic progenitor cells that have the ability to regulate immune responses. Adipose‐derived stromal/stem cells (ASCs), one of the types of MSCs, have the advantage of accessibility and potent immunomodulatory effects when compared with other MSCs, such as bone marrow‐derived MSCs. This study aimed to investigate the antifibrotic effect of ASCs in scleroderma mouse models, including bleomycin‐induced scleroderma and sclerodermatous chronic graft‐versus‐host disease (Scl‐cGVHD) models. Method ASCs were intravenously administered to a bleomycin‐induced scleroderma or Scl‐cGVHD model on day 0. We compared the skin and lung fibrosis of scleroderma model mice between the ASC‐treated group and control group. Results Administration of ASCs attenuated the skin and lung fibrosis of bleomycin‐induced scleroderma and Scl‐cGVHD model mice compared to that in the control mice. Immunohistochemical staining showed that ASCs suppressed the infiltration of CD4 + , CD8 + T cells and macrophages into the dermis of bleomycin model mice compared to that in control mice. In addition, ASCs attenuated the messenger RNA expression of collagen and fibrogenic cytokines, such as interleukin (IL)‐6 and IL‐13, in the skin of bleomycin model mice. ASCs also reduced the frequency of fibrogenic cytokine‐producing CD4 + T cells and effector B cells in the spleen of bleomycin model mice. Conclusion ASCs could prove to be a potential therapeutic agent for use in patients with SSc.